WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 220.127.116.11) - Pipeline Review, H1 2018”
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 18.104.22.168) - MAP kinase-interacting serine/threonine-protein kinase 2 is an enzyme encoded by the MKNK2 gene. It phosphorylates SFPQ/PSF, HNRNPA1 and EIF4E. It plays a role in the response to environmental stress and cytokines.
It appears to regulate translation by phosphorylating EIF4E thus increasing the affinity of this protein for the 7-methylguanosine-containing mRNA cap. It triggers EIF4E shuttling from cytoplasm to nucleus. It acts as a mediator of the suppressive effects of IFNgamma on hematopoiesis.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2967010-map-kinase-interacting-serine-threonine-protein-kinase-2-map-kinase
Top Companies mentioned
eFFECTOR Therapeutics Inc
Eli Lilly and Co
Merck & Co Inc
MAP Kinase Interacting Serine Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide MAP Kinase Interacting Serine - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for MAP Kinase Interacting Serine, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Diffuse Large B-Cell Lymphoma, Fragile X Syndrome, Hepatocellular Carcinoma, Inflammation, Lymphoma, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer and Solid Tumor.
MAP Kinase Interacting Serine - Competitive Analysis
Key players are making innovative developments in MAP Kinase Interacting Serine industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
The report provides a snapshot of the global therapeutic landscape for MAP Kinase Interacting Serine
The report reviews MAP Kinase Interacting Serine targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
The report reviews key players involved in MAP Kinase Interacting Serine targeted therapeutics and enlists all their major and minor projects.
The report assesses MAP Kinase Interacting Serine targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
The report summarizes all the dormant and discontinued pipeline projects.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2967010-map-kinase-interacting-serine-threonine-protein-kinase-2-map-kinase
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
P: +44 208 133 9349
M: +1 646 845 9349